Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 100,932,848
  • Shares Outstanding, K 1,634,540
  • Annual Sales, $ 20,776 M
  • Annual Income, $ 1,007 M
  • 36-Month Beta 1.02
  • Price/Sales 4.86
  • Price/Cash Flow 17.55
  • Price/Book 8.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 0.89
  • Number of Estimates 7
  • High Estimate 0.93
  • Low Estimate 0.86
  • Prior Year 0.75
  • Growth Rate Est. (year over year) +18.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
59.52 +4.59%
on 09/13/18
62.62 -0.58%
on 09/21/18
+2.17 (+3.61%)
since 08/21/18
3-Month
54.24 +14.77%
on 06/22/18
62.62 -0.58%
on 09/21/18
+8.31 (+15.41%)
since 06/21/18
52-Week
49.96 +24.60%
on 05/08/18
70.05 -11.13%
on 02/16/18
-1.08 (-1.71%)
since 09/21/17

Most Recent Stories

More News
Bristol-Myers' MM Drug Empliciti Application Validated by EMA

Bristol-Myers' (BMY) application for multiple myeloma drug, Empliciti gets validated in Europe.

CELG : 87.72 (-0.66%)
MRK : 71.10 (+0.45%)
ABBV : 92.26 (-0.45%)
BMY : 62.25 (+0.81%)
California Life Sciences Association Names Winners of 15th Annual Pantheon DiNA(TM) Awards, Honoring Innovation in Life Sciences

--Trade association representing industry to recognize pioneers for contributions to California's life sciences sector at 15th Annual Pantheon Awards Program, Nov. 30 in San Francisco

AMGN : 205.10 (unch)
BMY : 62.25 (+0.81%)
Is Bristol-Myers Squibb (BMY) a Great Dividend Play?

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.

BMY : 62.25 (+0.81%)
Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff

Novo Nordisk (NVO) plans to restructure and reallocate resources in its Research and Development organization and lay off 400 employees from the unit.

NVO : 47.66 (+0.34%)
LLY : 106.33 (+0.25%)
RHHBY : 30.6200 (+0.07%)
BMY : 62.25 (+0.81%)
Osteosarcoma - Pipeline Review (H2 2018) Featuring Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Merck, Pfizer, and more - ResearchAndMarkets.com

The "Osteosarcoma - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.Osteosarcoma - Pipeline Review, H2 2018, provides comprehensive information...

AMGN : 205.10 (unch)
BMY : 62.25 (+0.81%)
Aduro's Cancer Arm & Strong Collaborations Boost Growth

Aduro focuses on a broad pipeline of novel immunotherapies, developed for treating various types of cancers. Its collaboration agreements with large pharma companies fetch in regular funds.

JNJ : 142.88 (+0.63%)
NVS : 85.46 (-0.59%)
ADRO : 6.20 (-1.59%)
BMY : 62.25 (+0.81%)
Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern

Bayer (BAYRY) focuses on acquisitions and deals in order to boost growth as well as portfolio.

BAYRY : 22.5000 (+0.04%)
LLY : 106.33 (+0.25%)
RHHBY : 30.6200 (+0.07%)
BMY : 62.25 (+0.81%)
Cytori's Chemotherapy Candidate Gets Orphan Drug Status

Cytori Therapeutics' (CYTX) chemotherapy candidate, ATI-1123, gets orphan drug status from the FDA for small cell lung cancer.

LGND : 259.84 (+0.80%)
CYTX : 0.41 (-8.89%)
ILMN : 358.16 (+0.52%)
BMY : 62.25 (+0.81%)
Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?

Pfizer's (PFE) latest anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant long-term top-line driver for the company.

AZN : 37.68 (-0.11%)
MRK : 71.10 (+0.45%)
PFE : 44.06 (+0.71%)
BMY : 62.25 (+0.81%)
European Medicines Agency Validates Bristol-Myers Squibb's Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Multiple Myeloma

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Medicines Agency (EMA) has validated the Company's type II variation application for Empliciti (elotuzumab)...

BMY : 62.25 (+0.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade BMY with:

Business Summary

Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious...

See More

Key Turning Points

2nd Resistance Point 63.07
1st Resistance Point 62.66
Last Price 62.25
1st Support Level 61.79
2nd Support Level 61.34

See More

52-Week High 70.05
Fibonacci 61.8% 62.38
Last Price 62.25
Fibonacci 50% 60.01
Fibonacci 38.2% 57.63
52-Week Low 49.96

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar